Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2021-05-05
Target enrollment:
Participant gender:
Summary
This is a Phase 1B, randomized, participant- and investigator-blinded, placebo-controlled,
multi-center clinical trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamics
(PD), and biomarkers of inhaled GB002 in adults with World Health Organization (WHO) Group 1
Pulmonary Arterial Hypertension (PAH).
Phase:
Phase 1
Details
Lead Sponsor:
GB002, Inc. GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.